Germany: Overview of the 14th Amendment of the German Drug Act

Last Updated: 3 May 2006
Article by Marc Christian Bauer and Antje-Katrin Heinemann


The 14th Amendment of the German Drug Act came into force on 6 September 2005 making Germany the first EU member state to transpose the revised EU Pharmaceutical Legislation1 into national law. This article provides an overview of the contents and highlights some of its key provisions.


Altogether the 14th Amendment reflects an almost one-to-one implementation of the revised EU Pharmaceutical Legislation. An exception constitutes the "compassionate use", the renewals of marketing authorisations and the "sunset clause". The German legislator used the flexibility offered by the EU Pharma Legislation in this regard. The implications of the 14th Amendment are not limited to the German Drug Act (Arzneimittelgesetz – "AMG"). The Drug Advertising Act (Heilmittelwerbegesetz – "HWG"), the Patent Act (Patentgesetz – "PatG") and the Hospitals’ Fees Act (Krankenhausentgeltgesetz – "KEntgG") as well as the National Ordinance on Hospital Rates (Bundespflegesatzverordnung – "BPflV") have also been affected.

2.1 German Drug Act

Several key changes to the AMG are:

  1. Ready Prepared Medicinal Products
  2. According to Sec. 4 para. 1 of the AMG the definition of ready prepared medicinal products ("Fertigarzneimittel") includes products to be placed on the market which are manufactured and packaged in advance. This has been extended by the 14th Amendment. Products manufactured in any other way not necessarily "in advance" are also included. The extension of the scope of Sec. 4 para. 1 AMG affects the necessity of a marketing authorisation. A marketing authorisation is in principle necessary with respect to every industrial or commercial manufacturing of a medicinal product. However, products manufactured in pharmacies and unfinished products to be further processed by a manufacturer are excluded from the scope of Sec. 4 para.1 AMG.

  3. Pharmaceutical Entrepreneur
  4. Prior to the 14th Amendment, Sec. 4 para. 18 AMG stipulated that a pharmaceutical entrepreneur was any person placing medicinal products under his own name onto the market. Sec. 4 para. 18 AMG now clarifies that holders of a marketing authorisation or a registration are also pharmaceutical entrepreneurs. As to co-marketing ("Mitvertrieb") the amendment of Sec. 4 para. 18 AMG does not affect the legal position.

  5. Manufacturing
  6. The definition of "manufacturing" has been extended. Following the 14th Amendment to Sec. 4 para. 14 AMG, release of the product now constitutes a part of the manufacturing process. "Product release" is defined as supervision of a batch having been produced and checked according to the applicable regulations and in the case of authorised medicinal products also according to the requirements of the marketing authorisation. The product release requires a manufacturing licence according to Sec. 13 AMG. If subcontractors (for example, contract manufacturers) perform product releases they have to apply for a manufacturing licence. As the holder of a manufacturing licence the subcontractor can also be subject to product liability laws.

  7. Qualified person
  8. Prior to the 14th Amendment a manufacturing licence applicant had to appoint a head of quality control and a head of production. Following the amendments to Sec. 14-15 AMG, the applicant of a manufacturing licence has to appoint a qualified person. The person appointed as a qualified person must either have a licence to practise pharmacy or hold a university degree in pharmacy, chemistry, biology or human or veterinary medicine. The person shall also have at least two years practical quality control experience. In addition, the manufacturing licence applicant has to appoint a head of production and a head of control. The appointed persons have to be duly qualified and experienced. The qualified person can be either head of production or head of quality control but not both. The only exception applies to the production of medicated feed.

  9. Marketing authorisation
  10. According to Sec. 31 para. 1a AMG, marketing authorisations already renewed as of 1 January 2001 are valid for an unlimited period. However, the competent authorities are entitled to limit the renewal period to five years on the basis of any negative pharmacovigilance concerns regarding the safe placement of the medicinal product onto the market.

    Pursuant to Sec. 31 para. 1 no. 1 AMG (the "sunset clause") a marketing authorisation expires if a medicinal product is not placed onto the market within three years after issue of the marketing authorisation. The same applies to a medicinal product that has been off the market for three years. If the active ingredients of medicinal products have been placed onto the market within the European Union for at least ten years, no pharmaceutical and toxicological documentation is required for the application relating to marketing authorisations ("well established use"; Sec. 22 para. 3 no. 1 AMG).

    Before the 14th Amendment came into force patients could only be treated with non-authorised medicinal products in an emergency. Pursuant to Sec. 21 para. 2 no. 6 AMG it is now permissible to provide medicinal products to a patient if a marketing authorisation application is pending under the centralised authorisation procedure, provided the patient is suffering from a life threatening illness or an illness causing serious disability and he cannot be sufficiently treated with an authorised medicinal product. In addition it is possible to provide medicinal products to patients if the products are being tested in clinical trials and there is sufficient evidence of their efficacy and safety ("compassionate use").

  11. Labelling, patient information and summary of product characteristics
  12. The German law (Sec. 10–11 AMG) directly adopted the European Directives regarding labelling, patient information and summary of product characteristics. Thus the legal content and formal requirements have been harmonised with European law. The transitional period in this regard will end on 1 January 2009.

  13. Periodic safety update reports
  14. Pursuant to Sec. 63b para. 5 AMG the frequency for filing periodic safety update reports (PSURs) has been reduced from five to three years. During the period between the issue of the marketing authorisation and the placement onto the market the pharmaceutical entrepreneur has to file PSURs every six months. The same applies to the first two years after placement onto the market.

  15. Dossier protection
  16. In relation to authorisation for generics, the dossier protection for the reference medicinal product has been reduced to eight years. If an application for a marketing authorisation is filed in the eight year dossier protection period the authorities are not allowed to refer to the dossiers of the reference medicinal product. Two additional years of market exclusivity are also granted and the exclusive marketing period can be extended for another year, if within the eight years of the dossier protection period the marketing authorisation is broadened to further indications and the extension of indications shows a significant therapeutic benefit. The new protection periods ("8+2+1") apply only to those products that are authorised after 30 October 2005.

  17. Generics

The definition of generics according to a judgement of the European Court of Justice2 is now statutorily implemented in the AMG. Pursuant to Sec. 24b para. 2 AMG a generic has to consist of the same compound, the same pharmaceutical form and the same biological equivalence.


Pursuant to Sec. 11 no. 2b PatG patent protection does not extend to studies and trials and the consequential practical requirements that are obligatory in order to receive European marketing authorisation. According to the wording of Sec. 11 no. 2b PatG the "Bolar" exemption allows both generic testing as well as further research.


Furthermore, provisions of the HWG have been amended. The revisions only apply to advertising to the general public. The scope of the HWG and its restrictions have been extended to commercial statements regarding cosmetic surgery without medical indication. Additionally, according to Sec. 4a para. 2 HWG, it is not possible to advertise by making claims to consumers that a certain product is reimbursable by public sick funds.


The German Federal Social Court held in a well publicised judgement that German sick funds are not obliged to cover the costs of basic care of hospitalised patients that are participating in clinical trials with unapproved investigational products. The pharmaceutical entrepreneur who sponsors the clinical trial would have to bear these costs. The judgement has been criticised as unbalanced and inappropriate. The legislator has revised this judgment with the 14th Amendment. Now German sick funds have to cover the costs for basic care for all patients that are hospitalised for reasons other than a clinical trial (Sec. 8 KEntgG, Sec. 10 BPflV). The pharmaceutical entrepreneur is obliged only to pay for the additional costs related to the clinical trial such as investigational medicinal products, additional analysis or any prolonged stay in hospital.


1 Directive 2004/27/EC on the Community Code relating to medicinal products for human use; Directive 2004/28/EC on the Community Code relating to medicinal products for animal use; Directive 2004/24/EC on traditional herbal medicinal products; Directive 2004/23/EC on setting standards of quality and safety for the donation procurement, testing, processing, preservation, storage and distribution of human tissues and cells; Regulation EC/726/2004 on Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

2 Generics Ltd. – Official Journal of the European Union C 368/96.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions